HAVCR2 and cancer: Moreover, high TIM‐3 was identified as a potential predictor of poor outcome after anti‐PD‐1/PD‐L1 in some of those cancers, perhaps because the tumors take advantage of the TIM‐3 checkpoint to inactivate the immune system.17